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Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted 
Patients with Coronary Artery Disease 
Afsaneh Forood MD1, Reza Malekpour-Afshar MD2, Amin Mahdavi MD3 
 
Abstract 
Background: Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with inhibitory effects on the 
formation of plasmin from plasminogen by plasminogen activator. Thus, it prevents clot lysis in vessel walls. 
Several evidences prove the relationship between coronary artery disease and response to fibrinolytic therapy 
in patients with myocardial infarction (MI) with PAI-1 level. Opium addiction is one of the most important 
factors in causing MI and cardiovascular events. This is due to it causing imbalance between coagulation and 
anticoagulation factors in the blood. This study was designed and implemented to determine the levels of 
PAI-I in opium-addicted patients with coronary artery disease in comparison with non addicts. 
Methods: In this case-control study, 160 patients with coronary heart disease (CHD), which was confirmed by 
angiography results, were enrolled. All of the patients had a medical history, their creatinine levels and lipid 
profile were evaluated, morphine urine test was performed, and after that a blood sample was taken to 
determine the levels of PAI-1. Thus, the 80 patients who had a positive morphine urine test result formed the 
case group, and the control group was constituted of the 80 patients with negative morphine test results. The 
two groups were matched. 
Findings: Average level of PAI-1 in the control group was 2.4 ± 2.6 and in the case group was 8.8 ± 9.1 and it 
was statistically significant (P < 0.001). The frequency of two vessel disease was higher in opium addicted 
patients than non-addicted patients and this was statistically significant (P = 0.030). However, the frequency 
of single vessel and three vessel disease was the same in the two groups. The two groups had no differences in 
age, lipid profile, and creatinine level. Moreover, females are at a higher risk of high PAI-1 levels. 
Conclusion: PAI-1 levels in opium addicted patients with CHD are higher than other patients. In these 
patients, the risk of atherosclerosis and MI is higher than normal. 
Keywords: Opium addiction, Coronary heart disease, Plasminogen activator inhibitor-I (PAI-1) 
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Introduction 
Plasminogen is an important factor in the internal 
fibrinolysis system and it is mainly synthesized in 
the liver and exists as inactivated form in plasma. 
It converts to its active form by plasminogen 
activator and causes decomposition of clots. In 
other words, it prevents the formation of 
intravascular thrombus. One way of inhibiting 
physiological fibrinolysis system is applied by 
plasminogen activator inhibitor-1 (PAI-1). In 
normal conditions balance exists between tissue 
plasminogen activators and plasminogen 
activator inhibitor-I.1,2 
PAI-1 is a type of glycoprotein, and its gene is 
located on chromosome 7.3 Moreover, its 
production is exacerbated by endothelial cells, 
hepatocytes, and fibroblasts in conditions such as 
local homeostasis and in the presence of 
endotoxin and cytokines.3 This glycoprotein, with 
its inhibitory effect on plasminogen activator, 
prevents the formation of plasmin. In the early 
morning, PAI-1 levels naturally rise, but 
plasminogen activator levels do not change. It 
seems that during early morning, the activity of 
the fibrinolysis system reduces and intravascular 
thrombus formation tends to be high. Perhaps this 
is one of the main causes of heart attack during 
early mornings.4  
Several studies have shown the relationship 
between levels of plasminogen activator inhibitor-
1, and either stable or unstable coronary artery 
disease.5,6 However, in patients with MI, there is a 
clear association between PAI-1 levels and patient 
response to treatment with fibrinolytic agents; this 
has been demonstrated in several studies.7 PAI-1 
level is influenced by several factors such as 
patients’ age, renal insufficiency, systolic blood 
pressure, insulin resistance, obesity, and 
triglyceride levels; however, it is not associated 
with cholesterol levels and smoking.8  
There is increasing evidence indicating the 
importance of the internal fibrinolysis system and 
particularly PAI-1 level in the progression of 
atherosclerosis and that inhibiting glycoproteins 
can inhibit the development of atherosclerosis or 
even treat it. Thus, there are wide ongoing 
activities for the invention of compounds that 
inhibit the function of PAI-1. Although there is 
still no available combination that is approved for 
clinical use in humans, promising progress has 
been made in this field.9 In recent years, opium 
addiction has been taken into account as a risk 
factor for coronary artery disease, MI, and 
complications after coronary artery bypass 
surgery (graft occlusion).10,11 Based on the 
evidence, this effect may be caused by increased 
inflammatory mediators by opium and disruption 
of the balance between coagulation and 
anticoagulation factors.12 
Despite evidence regarding the role of opium 
in the advancement of atherosclerosis, so far, no 
study has been performed on its effects on plasma 
PAI-1 levels. In addition, based on clinical 
experiences, addicted patients with MI showed 
weaker response to treatment with thrombolytic 
drugs. The risk of stent stenosis and MI was 
higher in addicts than non-addicts, which could 
be due to the adverse impact of opium on the 
fibrinolysis system. In addition, due to the 
prevalence of opium addiction among patients in 
Iran, it is necessary to know the role of opium 
addiction and the appropriate respond for the 
prevention and treatment of these patients. 
Therefore, this study examined the effects of 
opium addiction on serum levels of PAI-1 in 
patients with coronary artery disease. Thus, the 
specialists in the field of health and macro-health 
system planners are provided with the required 
knowledge to plan and treat these patients 
according to an appropriate clinical approach. 
Methods 
This was a case-control study, conducted on 
patients with coronary artery disease who were 
hospitalized at Shafa Hospital affiliated to 
Kerman University of Medical Sciences, Iran. 
Patients who were undergoing coronary 
angiography and had over 70% stenosis in at least 
one coronary artery, an age of less than 65 years, 
body mass index below 30, and had no history of 
diabetes, kidney failure, liver disease, and 
hypertriglyceridemia. Despite the confounding 
effect of hypertension on PAI-1 levels, due to 
limited sample size, the patients with 
hypertension were not excluded from the study 
and its impact on the statistical analysis was 
considered. The case group consisted of opium 
addicts who had inhaled, ingested, or used opium 
as skewered stones or in the form of molasses, 
burnt, heroin, and etcetera, for at least three times 
a week for at least three consecutive years. 
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Patients who were not addicts, proven by their 
history and urine morphine strip test, were 
enrolled as control group. 
Before entering the study, the researcher gave 
the necessary explanations regarding the goals 
and methods of the study to the patients or those 
accompanying them, and they were allowed to 
ask questions about the study. They were also 
assured that all information will remain 
confidential and unwillingness to participate in 
the study will not affect the normal process of 
treatment. Written informed consents were 
eventually obtained from all patients.  
The patients’ demographic data, including age, 
gender, height, weight, blood pressure, 
biochemical findings, and the history and amount 
of opium consumption, were recorded by the 
investigator in the data collection form. 
Angiographic films were reviewed by two 
physicians specializing in cardiovascular disease. 
Moreover, having coronary artery disease (70% 
stenosis in at least one coronary artery) was 
checked and recorded in the data collection form 
for each patient. Then, venous blood samples 
were taken from each patient in the morning of 
angiography after 12 hours fasting, and were kept 
for PAI-1 measurement in a temperature below  
20 °C.  
Finally, after collecting blood samples from all 
patients participating in the study, PAI-1 was 
measured by enzyme-linked immunosorbent 
assay (ELISA) kit (KHC3071 manufactured by 
Invitrogen®) and the data were entered into the 
data collection forms. All collected data were 
entered into SPSS for Windows (version 16, SPSS 
Inc., Chicago, IL, USA) for analysis and were 
analyzed by central frequency indicators and 
distribution, Student’s t-test, and chi-square test. 
In order to remove the effects of confounding 
variables, single univariate and multivariate 
regressions were used. 
Results 
In the present study, 160 patients with coronary 
artery disease were included; 80 patients entered 
into the study group and 80 patients in the control 
group. Of these patients, 106 were males (66.3%) 
and 54 were females (33.8%). The overall mean 
age of the patients was 53.8 ± 6.2, and the 
youngest patient was 40 years old and the oldest 
was 65 years old. Demographic characteristics of 
the two groups, including age, gender, body mass 
index (BMI), fasting blood sugar, and blood fat 
index, are shown in table 1. In all the cases of the 
demographic characteristics, except male gender, 
in both groups the differences were not 
statistically significant (P > 0.050). 
The mean dosage used in the addicts group 
was 6.7 ± 3.5. Regarding the method of 
consumption of opium, 16 (20%) used it orally, 40 
(50%) by inhalation, and 24 (30%) as skewer stone. 
Regarding the duration of addiction to opium, 1 
patient (1.3%) had an addiction for three years, 5 
patients (6.3%) between three to five years, and 74 
patients (92.5%) for more than five years. Results 
of the involvement of coronary heart disease 
(CHD) in patients of both groups are shown in 
table 2. The patients of the case group, compared 
to the control group, had higher levels of 
involvement, which was two-vessel disease and 
was statistically significant (P = 0.030).  
Average PAI-1 in all patients was 5.6 ± 7.9 
ng/ml. This amount in the two groups of addicts 
and non-addicts was 8.8 ± 9.1 and 2.4 ± 2.6, 
respectively, and this difference between the two 
groups of control and case was significant  
(P < 0.001). 
Due to the lack of normal distribution of 
amount of PAI-1, logarithm of the concentration 
of PAI-1 was used to compare the levels of this 
 
Table 1. Demographic characteristics of the patients in both case and control groups 
Variables Addicts Non-addicts P 
Age (year) 54.0 ± 6.4 53.6 ± 5.9 0.700 
BMI (kg/m2) 26 ± 2 26 ± 2 0.500 
Gender [male (%)] 60 46 0.019 
Triglycerides (mg/dl) 131 ± 24 138 ± 26 0.090 
Creatinine (mg/dl) 0.9 ± 0.2 0.9 ± 0.4 0.560 
FBS (mg/dl) 102 ± 11 101 ± 12 0.470 
History of high blood pressure (%) 28 30 0.700 
BMI: Body mass index; FBS: Fasting blood sugar 
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Table 2. Frequency of involvement of coronary artery 
disease in two case and control groups 
Variables Case group Control group 
n (%) 
One vessel disease 22 (27.5) 42 (52.5) 
Two vessel disease 46 (57.5) 26 (32.5) 
Three vessel disease 12 (15.0) 12 (15.0) 
 
enzyme in the two study groups. The mean level 
of PAI-1 in the addicts’ group was 0.7 ± 0.49 and 
in the case group was 0.14 ± 0.46, and this 
difference was statistically significant (P < 0.001). 
Using univariate linear regression model and 
logarithm of PAI-1 as the dependent variable, the 
impact of demographic and clinical variables on 
the level of PAI-1 were also examined. Based on 
these results there was a significant relationship 
between opium addiction and PAI-1 levels  
(P < 0.001, β = 0.56). The impact of these variables 
on the level of PAI-1, using this model, is shown 
in table 3. 
With regard to the likely effect of confounding 
variables on the relationship between addiction 
and PAI-1 level, multivariate linear regression 
model was used to examine the effect of variables 
with a P value of less than 0.2 in the univariate 
method. In other words, the only variables that 
were entered into multivariate models were 
variables that had a P value less than 0.2 in the 
univariate model. The results of this model 
showed that opium addiction was still 
significantly increasing the levels of PAI-1  
(P < 0.001, β = 0.522). In this model, there was a 
significant relationship between female gender 
and level of this inhibitor (P < 0.001). In other 
words, female gender was an independent risk 
factor for increased levels of PAI-1. Furthermore, 
between cigarette smoking and levels of this 
inhibitor, there was a significant boundary 
relationship (P = 0.058). This means that smoking 
was determined as an independent risk factor for 
increasing the level of PAI-1. The related data are 
shown in table 4. 
Discussion 
This study, which was conducted on opium 
addicted and non-addicted patients with CHD, 
showed that the serum levels of PAI-1 in patients 
with opium addiction was about four times that in 
non-addicted patients. PAI-1 serum levels were 
higher in addicted patients and had no relationship 
with the dosage used.  
Today, the defects of fibrinolytic activity have 
been identified in the case of atherothrombotic 
vascular disease.13,14 This flaw in the occurrence of 
 
Table 3. The impact of demographic and clinical variables on PAI-1 index using univariate 
linear regression LOG (PAI-1) 
Variables Β (Beta) SE P 
Gender (female) 0.307 0.087 0.001 
BMI (km/m2) -0.033 0.018 0.066 
Triglyceride (mg/dl)  0.000 0.002 0.923 
Cholesterol (mg/dl) -0.003 0.002 0.075 
Smoking (pack/year) 0.180 0.094 0.058 
CAD intensity  0.048 0.053 0.365 
Opium addict or non-addict 0.522 0.625 < 0.001 
BMI: Body mass index; CAD: Coronary artery disease; SE: Standard error 
 
Table 4. Multivariate linear regression 
Variables Β (Beta) SE P 
Gender (female ) 0.307 0.087 0.001 
BMI (km/m2) -0.033 0.018 0.066 
Triglyceride (mg/dl)  0.000 0.002 0.923 
Cholesterol (mg/dl) -0.003 0.002 0.075 
Smoking (pack/year) 0.180 0.094 0.058 
CAD intensity  0.048 0.053 0.365 
Opium addict or non-addict 0.522 0.625 < 0.001 
BMI: body mass index; CAD: Coronary artery disease; SE: Standard error 
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diseases, such as myocardial infarction (MI) and 
stroke, has been proven. However, its relationship 
with atherosclerosis is not yet known.15,16 In 
patients with cardiovascular disease, especially in 
patients with a history of MI or acute coronary 
syndrome (ACS), impaired fibrinolytic activity 
was observed at rest and after physical activity 
and this disorder was associated with increased 
levels of PAI-1 in blood.17,18 In addition, PAI-1 
activity in patients with diabetes mellitus with MI 
is very high.19 Moreover, PAI-1 activity and very-
low-density lipoprotein (VLDL), and triglyceride 
levels, respectively, had a positive and negative 
relationship with insulin sensitivity.20 High levels 
of PAI-1 is considered as a predictive factor in the 
incidence of MI.21  
Previous studies have shown that plasma 
fibrinogen levels in men with opium addiction are 
higher than men with CHD.12 Studies have also 
showed a positive relationship between serum 
levels of fibrinogen and the incidence of MI.22,23 It 
has also been shown that fibrinogen levels have 
increased the possibility of vessel lumen 
involvement.22 Based on the findings of this study, 
the frequency of two-coronary vessel occlusion was 
increased in patients with addiction compared to 
non-addict patients, which confirmed the results of 
previous studies.24 It Seems that with increased 
levels of fibrinogen and PAI-1 in patients addicted 
to opium, the rate of cardiac and cerebral artery 
occlusion also increased.  
Some people and even a few doctors believe 
that opium can be effective in the prevention and 
mitigation of cardiovascular diseases and diabetes. 
In this study, it was shown that lipid variables and 
creatinine levels in both control and case groups 
had no difference, which was consistent with the 
results obtained from the study by Asgary et al.24 
However, in another study it was shown that 
morphine prescription increased levels of total 
cholesterol and LDL.25 Other studies also showed 
that PAI-1 levels were higher in patients with 
diabetes mellitus than in other patients, and that 
morphine injection increased blood sugar levels, 
despite the public perception.26 Therefore, it seems 
that opium addicted patients who have diabetes 
are at higher risk than other people. Presently, 
there has been no study to assess the level of PAI-1 
in patients with opium addiction, and this study, 
for the first time, examined PAI-1 level among 
these patients.  
Based on the findings of this study, female 
gender was a risk factor for increased PAI-1. 
Nevertheless, findings of the study by Sadeghian  
et al. showed that men with opium addiction were 
more at risk of heart disease than men with 
diabetes.27 It seems that in patients addicted to 
opium, due to the constant lipid parameters in 
comparison to other individuals and because of the 
positive relationship of these parameters with  
PAI-1 levels, lipid levels were higher. The present 
study confirmed this result. Followed by the high 
levels of PAI-1 in patients with opium addiction, 
the incidence of coronary artery lumen occlusion 
and cerebrovascular and cardiovascular diseases 
were higher than in normal individuals, and the 
reason for this is not yet clear.28 
Based on previous studies, regarding PAI-1 
serum levels in patients who were obese, PAI-1 
levels increased with increasing BMI.29 In the 
findings of this study, there was no significant 
relationship between PAI-1 levels and BMI amount 
in the patients of control and case groups. It 
appears that due to the compatibility between case 
and control groups and having BMI of more than 
26 among the patients, the PAI-1 levels increased 
with the same ratio. This theory was consistent 
with the study by Shimomura et al.30  
Studies showed that among the blood lipids, 
including triglycerides and cholesterol, only 
increased cholesterol levels caused the increased 
expression of PAI-1 in patients.31 In addition, other 
studies showed that increase in morphine 
consumption caused an increase in total cholesterol 
and LDL levels.25 However, the findings of this 
study did not show a significant relationship 
between increased levels of cholesterol or 
triglyceride and increased expression of PAI-1. It 
appears that in patients with high cholesterol 
levels, increased expression of PAI-1 occurs to an 
extent, and high cholesterol alone cannot increase 
PAI-1 levels. The results of the study by Vaisanen 
et al. also showed that increased blood cholesterol 
as LDL, has only a small role in increasing 
plasminogen and PAI-1 of patients.32  
Numerous studies on the role of smoking and 
increased levels of PAI-1 have shown that cigarette 
smoking increases the risk of heart attack. Smoking 
increases the risk of atherosclerosis and PAI-1, and 
causes MI.33 The findings of this study showed that 
smoking marginally increased PAI-1 levels 
resulting in a marginal increase, and it appears that 
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although smoking increased PAI-1, it had a small 
role in increasing its amount in the body, this was 
consistent with the findings of the study by 
Scarabin et al.34  
The limitations of this study were the lack of 
similarity between the gender of the participants of 
both groups and the impossibility of excluding 
patients with high blood pressure. It is 
recommended that these facts be considered in 
similar studies in the future. 
Conclusion 
Based on the findings of the current study, it was 
shown that in patients with opium addiction and 
CHD PAI-1 serum level was higher than other 
patients, and the extent of vascular occlusion and 
the risk of MI were higher than normal 
individuals. 
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